MedPageToday -- The investigational antibiotic fidaxomicin was as effective as vancomycin for treating Clostridium difficile diarrhea, a phase III, noninferiority trial showed. And the new agent resulted in lower rates of recurrence within four weeks of the end of treatment (15.4% versus 25.3%, P=0.005), Thomas Louie, MD, of the University of Calgary in Alberta, and colleagues reported in the Feb. 3 issue of the New England Journal of Medicine.
